Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

By LabMedica International staff writers
Posted on 07 Sep 2026

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026. More...

Rapid identification of suspected cases is critical for timely containment and coordinated public health response. Molecular assays that shorten time to actionable results are especially valuable in decentralized settings. A newly WHO-listed test now offers approximately one-hour detection of multiple hemorrhagic fever viruses to support the response.

Cepheid’s Xpert Hemorrhagic Fever Panel is a molecular diagnostic assay that runs on the company’s GeneXpert Dx systems. The test detects and identifies nucleic acids from Ebola virus (including Zaire, Sudan, Taï Forest, and Bundibugyo, not differentiated), as well as Crimean-Congo hemorrhagic fever virus, Marburg virus, and Lassa virus. Reported time to result is about one hour, enabling use in settings where rapid triage and isolation decisions are required.

WHO has granted Emergency Use Listing (EUL) for the Xpert Hemorrhagic Fever Panel to support diagnostic response during the current Ebola Bundibugyo outbreak in the DRC. The listing enables healthcare providers and public health authorities to leverage decentralized, rapid molecular testing to help identify suspected cases and support outbreak containment. Cepheid notes an extensive GeneXpert Dx system footprint across Africa that can facilitate rapid deployment where testing is needed.

The company cites more than a decade of experience in Ebola diagnostics, including deployment of its Xpert Ebola test under U.S. Food and Drug Administration Emergency Use Authorization during the 2014–2016 West Africa outbreak. In June 2026, an initial shipment of Xpert Hemorrhagic Fever tests was donated to support the DRC response. The test is U.S. FDA 510(k) cleared for use by the U.S. Department of Defense and included in the DoD’s Next Generation Diagnostics System 2 program. The assay is an in vitro diagnostic medical device and is not available in all countries.

“Rapid and accurate diagnostics is one of the most important tools for controlling outbreaks of highly infectious diseases such as Ebola. With an established footprint already serving communities across Central and East Africa, we are well positioned to support healthcare providers and public healthcare authorities with timely access to reliable diagnostic information. This listing reinforces our commitment to partnering with global health organizations to expand access to critical diagnostics where and when they are needed most—and is an example of how we solve the hardest problems together,” said Connie Savor, Chief Medical Officer at Cepheid.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.